Full Title
A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Daniel Danila’s office at 646-422-4612.
Protocol
26-024
Phase
Phase I/II (phases 1 and 2 combined)
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT07192614